Dr. Mei Dong
Claim this profileLegacy Good Samaritan Hospital and Medical Center
Area of expertise
Breast Cancer
Mei Dong has run 6 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Mei Dong has run 5 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
Legacy Good Samaritan Hospital And Medical Center
Legacy Salmon Creek Hospital
Clinical Trials Mei Dong is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
Chemotherapy vs Chemoradiotherapy
for Rectal Cancer
This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?
Recruiting
2 awards
Phase 3
More about Mei Dong
Clinical Trial Related
2 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Mei Dong has experience with
- Pembrolizumab
- Cabozantinib S-malate
- Paclitaxel
- Cyclophosphamide
- Doxorubicin
- Biospecimen Collection
Breakdown of trials Mei Dong has run
Breast Cancer
Breast cancer
Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mei Dong specialize in?
Mei Dong focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Mei Dong currently recruiting for clinical trials?
Yes, Mei Dong is currently recruiting for 5 clinical trials in Portland Oregon. If you're interested in participating, you should apply.
Are there any treatments that Mei Dong has studied deeply?
Yes, Mei Dong has studied treatments such as Pembrolizumab, Cabozantinib S-malate, Paclitaxel.
What is the best way to schedule an appointment with Mei Dong?
Apply for one of the trials that Mei Dong is conducting.
What is the office address of Mei Dong?
The office of Mei Dong is located at: Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon 97210 United States. This is the address for their practice at the Legacy Good Samaritan Hospital and Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.